Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Tsao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2001 - 2004
Indiana University School of MedicineResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
TX State Medical License 2001 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
American Board of Internal Medicine Medical Oncology- Join now to see all
Clinical Trials
- Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Start of enrollment: 2006 Aug 01
- BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC Start of enrollment: 2006 Nov 01
- Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer Start of enrollment: 2007 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Longitudinal Tracking of-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA.Simon Heeke, Saumil Gandhi, Hai T Tran, Vincent K Lam, Lauren A Byers
JTO Clinical and Research Reports. 2025-04-01 - 1 citationsAuthor Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01 - Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples.Nejla Ozirmak Lermi, Max Molina Ayala, Sharia Hernandez Ruiz, Wei Lu, Khaja Khan
Research Square. 2025-01-17
Lectures
- Changing the Concurrent Chemotherapy-Radiation Paradigm: Can We Replace Chemotherapy with...ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothel...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- Systemic treatment for unresectable malignant pleural mesotheliomaTsao AS, Vogelzang N
http://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma
UpToDate, Wolters Kluwer Health - 2013-04-15
Press Mentions
ECOG-ACRIN Research Highlights at ASCO 2022May 27th, 2022- New Mesothelioma Immunotherapy Clinical Trial Opens at MD AndersonMay 11th, 2022
- Raffit Hassan, MD, on Immunotherapy's Inroads in Malignant Pleural MesotheliomaMay 6th, 2022
- Join now to see all
Grant Support
- UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1UNIVERSITY OF TX MD ANDERSON CAN CTR2019–2025
- UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1UNIVERSITY OF TX MD ANDERSON CAN CTR2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
